Positive impactOrders & Deals
Mankind Pharma Q2 profit rises 38% to Rs 716 crore
Economic Times 1 hr ago·27 Oct 2026, 2:00 am
Mankind Pharma reported a 38% jump in Q2 profit, reaching Rs 716 crore, while revenue rose to about Rs 4,338 crore, up from Rs 3,697 crore a year earlier. The company said the improvement came from stronger sales in both its domestic market and overseas operations.
For investors, the higher profit margin suggests the firm is managing costs well and benefitting from demand for its product range. The recent purchase of Armed Cell Therapeutics is expected to boost its research and development capabilities, potentially expanding its pipeline and supporting longer‑term growth.
Going forward, traders will be watching how quickly the new acquisition is integrated, any updates on product pricing or regulatory clearances, and the next quarterly results for signs that the R&D push is translating into revenue.
Excerpt from Economic Times
(What's moving Sensex and Nifty Track latest market news , stock tips , Budget 2025 , Share Market on Budget 2025 and expert advice , on ETMarkets . Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)…Read the original at Economic Times
Affected stocks
Bullish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Mankind Pharma (MANKIND).
- Category: Orders & Deals.
- AI reads the tone as positive (potentially bullish) for the stock.
Why it matters
A routine update for Mankind Pharma. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
